Point72 Asset Management
ALLO icon

Point72 Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Point72 Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-221,335
Closed -$540K – 3957
2026
Q1 		$540K Buy
221,335
+117,595
+113% +$236K ﹤0.01% 3086
2025
Q4 		$142K Buy
+103,740
New +$137K ﹤0.01% 3696
2024
Q1 		– Sell
-679,468
Closed -$2.18M – 2141
2023
Q4 		$2.18M Buy
+679,468
New +$1.93M 0.01% 1175
2023
Q3 		– Sell
-2,217
Closed -$11K – 2425
2023
Q2 		$11K Buy
2,217
+119
+6% +$644 ﹤0.01% 1901
2023
Q1 		$10.4K Buy
+2,098
New +$13.5K ﹤0.01% 2035
2022
Q4 		– Sell
-293,200
Closed -$3.17M – 1493
2022
Q3 		$3.17M Buy
+293,200
New +$3.98M 0.01% 834

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Point72 Asset Management's ALLO Position: Q2 2026 in Review

Point72 Asset Management sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 221,335 shares — an estimated $540K sold.

Point72 Asset Management first reported a position in ALLO in Q3 2022 and held it in 6 quarters. The position peaked at $3.17M in Q3 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Point72 Asset Management reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 221,335 Allogene Therapeutics shares in Q2 2026, an estimated $540K.
  • Point72 Asset Management first reported a position in Allogene Therapeutics in Q3 2022 and held it in 6 quarters.
  • Point72 Asset Management's Allogene Therapeutics position peaked at $3.17M in Q3 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.